Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    February 2017
  1. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    January 2017
  2. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2017 Jan 5. pii: mdw695. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. PIERGA JY, Bidard FC, Autret A, Petit T, et al
    Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Ann Oncol. 2017;28:103-109.
    PubMed     Text format    


  4. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: a study on 35 441 individuals from the Danish general population.
    Ann Oncol. 2017;28:175-181.
    PubMed     Text format    


  5. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017;28:16-33.
    PubMed     Text format    


  6. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2017;28:44-56.
    PubMed     Text format    


    December 2016
  7. M-RABET M, Cabaud O, Josselin E, Finetti P, et al
    Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    Ann Oncol. 2016 Dec 20. pii: mdw678. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. KHOSROW-KHAVAR F, Filion KB, Al-Qurashi S, Torabi N, et al
    Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ann Oncol. 2016 Dec 20. pii: mdw673. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. PAGANI O, Klingbiel D, Ruhstaller T, Nole F, et al
    Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99.
    Ann Oncol. 2016 Dec 19. pii: mdw622. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. BELL R, Brown J, Parmar M, Toi M, et al
    Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  11. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2016.
    PubMed     Text format    


    November 2016
  13. CARDOSO F, Harbeck N, Barrios CH, Bergh J, et al
    Research needs in breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  14. LOIBL S, Jackisch C, Schneeweiss A, Schmatloch S, et al
    Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  15. MARTIN M, Chan A, Dirix L, O'Shaughnessy J, et al
    A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  16. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: A study on 35,441 individuals from the Danish general population.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  17. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  18. NITZ U, Gluz O, Huober J, Kreipe HH, et al
    Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
    Ann Oncol. 2016.
    PubMed     Text format    


    August 2016
  19. WOODS LM, Morris M, Rachet B
    No 'cure' within 12 years of diagnosis amongst breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989-2011.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  20. VUYLSTEKE P, Huizing M, Petrakova K, Roylance R, et al
    Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  21. MAVROUDIS D, Matikas A, Malamos N, Papakotoulas P, et al
    Dose-dense FEC followed by Docetaxel versus Docetaxel plus Cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  22. VRDOLJAK E, Marschner N, Zielinski C, Gligorov J, et al
    Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  23. DIECI MV, Prat A, Tagliafico E, Pare L, et al
    Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  24. DELALOGE S, Perol D, Courtinard C, Brain E, et al
    Paclitaxel plus Bevacizumab or Paclitaxel as First-line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  25. JERUSALEM G, Mariani G, Ciruelos EM, Martin M, et al
    Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm,
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  26. GOEL S, Krop IE
    PIK3CA mutations in HER2-positive breast cancer - an ongoing conundrum.
    Ann Oncol. 2016.
    PubMed     Text format    


    May 2016
  27. WINTER C, Nilsson MP, Olsson E, George AM, et al
    Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests one third of mutations are somatic.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  28. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  29. PIVOT X, Marme F, Koenigsberg R, Guo M, et al
    Pooled analyses of eribulin in metastatic breast cancer patients with at least 1 prior chemotherapy.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  30. MARTIN M, Fumoleau P, Dewar JA, Albanell J, et al
    Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: Results from a phase Ib/IIa study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  31. MITTENDORF EA, Ardavanis A, Symanowski J, Murray JL, et al
    Primary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  32. JACOT W, Firmin N, Roca L, Topart D, et al
    Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  33. HARBECK N, Iyer S, Turner N, Cristofanilli M, et al
    Quality of Life With Palbociclib Plus Fulvestrant in Previously Treated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Patient-Reported Outcomes From the PALOMA-3 Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  34. MICHIELS S, Pugliano L, Marguet S, Grun D, et al
    Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  35. LI J, Holm J, Bergh J, Eriksson M, et al
    Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.
    Ann Oncol. 2016.
    PubMed     Text format    


  36. MACKEY JR, Pienkowski T, Crown J, Sadeghi S, et al
    Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer - BCIRG-005 randomized trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  37. ABRAHAMS HJ, Gielissen MF, Schmits IC, Verhagen CA, et al
    Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: A meta-analysis involving 12,327 breast cancer survivors.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  38. TREDAN O, Follana P, Moullet I, Cropet C, et al
    A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  39. HUANG Z, Wen W, Zheng Y, Gao YT, et al
    Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  40. GLUZ O, Liedtke C, Huober J, Peyro-Saint-Paul H, et al
    Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  41. BONNEFOI H, Grellety T, Tredan O, Saghatchian M, et al
    A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  42. ZDENKOWSKI N, Forbes JF, Boyle FM, Kannourakis G, et al
    Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor positive breast cancer (ANZ0501 LATER): An open-label randomised controlled trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  43. RUSTHOVEN CG, Rabinovitch RA, Jones BL, Koshy M, et al
    The Impact of Postmastectomy and Regional Nodal Radiation after Neoadjuvant Chemotherapy for Clinically Lymph Node Positive Breast Cancer: A National Cancer Database (NCDB) Analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  44. BUTOW P, Phillips KA
    Medication to Reduce Breast Cancer Risk: Why is uptake low?
    Ann Oncol. 2016.
    PubMed     Text format    


    January 2016
  45. LEE ES, Jung SY, Kim JY, Kim JJ, et al
    Identifying the potential long-term survivors among breast cancer patients with distant metastasis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  46. NIIKURA N, Tomotaki A, Miyata H, Iwamoto T, et al
    Changes in Tumor Expression of HER2 and Hormone Receptors Status after Neoadjuvant Chemotherapy in 21,755 Patients from the Japanese Breast Cancer Registry.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  47. ECCLES DM, Li N, Handwerker R, Maishman T, et al
    Genetic testing in a cohort of young patients with HER2 amplified breast cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  48. HADJI P, Coleman RE, Wilson C, Powles TJ, et al
    Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  49. SMITH SG, Sestak I, Forster A, Partridge A, et al
    Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  50. RODRIGUEZ-WALLBERG K, Turan V, Munster P, Oktay K, et al
    Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
    Ann Oncol. 2015.
    PubMed     Text format    


  51. GEBHART G, Lamberts LE, Wimana Z, Garcia C, et al
    Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  52. PRUNERI G, Vingiani A, Bagnardi V, Rotmensz N, et al
    Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  53. LOBBEZOO DJ, van Kampen RJ, Voogd AC, Dercksen MW, et al
    In real life, one-quarter of patients with hormone receptor positive metastatic breast cancer receive chemotherapy as initial palliative therapy A study of the Southeast Netherlands Breast Cancer Consortium.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  54. TEMPLETON AJ, Seruga B
    Primum non nocere.
    Ann Oncol. 2015;26:2197-8.
    PubMed     Text format    


  55. AAPRO M, Moebus V, Nitz U, O'Shaughnessy J, et al
    Reply to letter to the editor 'Primum non nocere' by Templeton and Seruga.
    Ann Oncol. 2015;26:2198-9.
    PubMed     Text format    


    May 2014
  56. BALMANA J, Tung NM, Isakoff SJ, Grana B, et al
    Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: